Found: 115
Select item for more details and to access through your institution.
Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies.
- Published in:
- Disease Markers, 2012, v. 32, n. 4, p. 221, doi. 10.1155/2012/873749
- By:
- Publication type:
- Article
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 23, p. 5505, doi. 10.3390/cancers15235505
- By:
- Publication type:
- Article
Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 5, p. 1466, doi. 10.3390/cancers15051466
- By:
- Publication type:
- Article
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2394, doi. 10.3390/cancers12092394
- By:
- Publication type:
- Article
The Roles of Imprinted SLC22A18 and SLC22A18AS Gene Overexpression Caused by Promoter CpG Island Hypomethylation as Diagnostic and Prognostic Biomarkers for Non-Small Cell Lung Cancer Patients.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2075, doi. 10.3390/cancers12082075
- By:
- Publication type:
- Article
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.
- Published in:
- BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-656
- By:
- Publication type:
- Article
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.
- Published in:
- 2014
- By:
- Publication type:
- journal article
PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Treatment rationale and study design for a phaseIII, double-blind, placebo-controlled study ofmaintenance pemetrexed plus best supportivecare versus best supportive care immediatelyfollowing induction treatment with pemetrexedplus cisplatin for advanced nonsquamousnon-small cell lung cancer
- Published in:
- BMC Cancer, 2010, v. 10, p. 85, doi. 10.1186/1471-2407-10-85
- By:
- Publication type:
- Article
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
- Published in:
- Molecular Cancer, 2024, v. 23, p. 1, doi. 10.1186/s12943-024-02014-x
- By:
- Publication type:
- Article
Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis.
- Published in:
- Oncologist, 2023, v. 28, n. 6, p. e406, doi. 10.1093/oncolo/oyad078
- By:
- Publication type:
- Article
Genomic Profiling of HER2‐Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2‐Positive Advanced Gastric Cancer Treated with Trastuzumab.
- Published in:
- Oncologist, 2018, v. 23, n. 9, p. 1092, doi. 10.1634/theoncologist.2017-0379
- By:
- Publication type:
- Article
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.
- Published in:
- Journal of Cellular & Molecular Medicine, 2014, v. 18, n. 8, p. 1519, doi. 10.1111/jcmm.12278
- By:
- Publication type:
- Article
Reply to Watkins and Rukazenkov (J Cell Mol Med 2010), re-Letter of Response to manuscript entitled 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14(1-2): 51-69).
- Published in:
- Journal of Cellular & Molecular Medicine, 2011, v. 15, n. 5, p. 1225, doi. 10.1111/j.1582-4934.2011.01295.x
- By:
- Publication type:
- Article
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.
- Published in:
- Journal of Cellular & Molecular Medicine, 2010, v. 14, n. 1/2, p. 51, doi. 10.1111/j.1582-4934.2009.00991.x
- By:
- Publication type:
- Article
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation- Positive Metastatic Non—Small-Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non--Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2014, v. 15, n. 6, p. 418, doi. 10.1016/j.cllc.2014.06.007
- By:
- Publication type:
- Article
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or...
- Published in:
- Clinical Lung Cancer, 2012, v. 13, n. 6, p. 500, doi. 10.1016/j.cllc.2012.05.009
- By:
- Publication type:
- Article
Corrigendum to “Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer”.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.
- Published in:
- Cells (2073-4409), 2019, v. 8, n. 8, p. 806, doi. 10.3390/cells8080806
- By:
- Publication type:
- Article
Safety of eribulin as third‐line chemotherapy in HER2‐negative, advanced breast cancer pre‐treated with taxanes and anthracycline: OnSITE study.
- Published in:
- Breast Journal, 2019, v. 25, n. 2, p. 219, doi. 10.1111/tbj.13199
- By:
- Publication type:
- Article
Durvalumab in NSCLC: latest evidence and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758835918804151
- By:
- Publication type:
- Article
Treating KRAS-mutant NSCLC: latest evidence and clinical consequences.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 9, p. 589, doi. 10.1177/1758834017719829
- By:
- Publication type:
- Article
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00482-2
- By:
- Publication type:
- Article
Tumor–Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread.
- Published in:
- Biomedicines, 2021, v. 9, n. 4, p. 364, doi. 10.3390/biomedicines9040364
- By:
- Publication type:
- Article
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Targeting KRAS<sup>G12C</sup> in Non-Small-Cell Lung Cancer: Current Standards and Developments.
- Published in:
- Drugs, 2024, v. 84, n. 5, p. 527, doi. 10.1007/s40265-024-02030-7
- By:
- Publication type:
- Article
Targeting EGFR in Lung Cancer: Current Standards and Developments.
- Published in:
- Drugs, 2018, v. 78, n. 9, p. 893, doi. 10.1007/s40265-018-0916-4
- By:
- Publication type:
- Article
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01464-y
- By:
- Publication type:
- Article
Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 11, p. 2462
- By:
- Publication type:
- Article
Review of a promising new agentpemetrexed disodium (Based on a Satellite Symposium held in conjunction with the First European Conference on Perspectives in Bladder Cancer, Monte Carlo, Monaco, November 1617, 2001.).
- Published in:
- Cancer (0008543X), 2003, v. 97, p. 2056
- By:
- Publication type:
- Article
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
- Published in:
- Cancer (0008543X), 2002, v. 95, n. 4, p. 751, doi. 10.1002/cncr.10762
- By:
- Publication type:
- Article